BriaCell Pioneering Immunotherapy For Advanced Breast Cancer Treatment

BriaCell Therapeutics (TSX:BCT, OTC:BCTXF) CEO Dr. Bill Williams was recently featured in an article by BioTuesdays outlining the company’s progress in the field of immunotherapy. According to the report, BriaCell’s lead drug candidate Bria-IMT completed a Phase 1/2a clinical study in December, returning impressive early efficacy data. Bria-IMT incorporates BriaCell’s industry-leading immunotherapy technology which repurposes the body’s immune system to destroy cancerous cells, resulting in fewer side effects than traditional chemotherapy.

“Right now, there is no immunotherapy that works by itself against advanced breast cancer, an unmet medical need that was responsible for more than 40,000 deaths in the U.S. in each of 2017 and 2018,” said Dr. Bill Williams, president and CEO of BriaCell. The company hopes to develop additional combination immunotherapies to try alongside Bria-IMT in the future.

BriaCell is currently in development of a number of immunotherapy solutions, including Bria-OTS, an off-the-shelf personalized immunotherapy system.

To read more about BriaCell’s progress in the field of immunotherapy click here.

Click here to connect with BriaCell Therapeutics Corp (TSX:BCT, OTCQB:BCTXF) for an Investor Presentation.